In conclusion, we show that MSC therapy can suppress the excessive inflammatory response in ARDS, and this effect occurs through the CAP and the nAChR-dependent suppression of proinflammatory cytokine production. This evidence concerns the gene CHRNA4 and acute respiratory distress syndrome.